Duke University Hospital

Burn Boot Camp and Muscular Dystrophy Association Team Up for 8th Annual 'Be Their Muscle' Philanthropic Event

Retrieved on: 
Monday, March 25, 2024
Research, Employment, Entrepreneurship, Skeletal muscle, MDA, ALS, Partnership, Air travel, Education, Duke University Hospital, Social media, Muscular dystrophy, Muscular Dystrophy Association, Senior, Empowerment, Duchenne muscular dystrophy, Duchenne, Clinical trial, FDA, Summer camp, Pharmaceutical industry

Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.

Key Points: 
  • Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual national 'Be Their Muscle' philanthropic event.
  • Muscular Dystrophy Association is one of Burn Boot Camp's longest-standing national philanthropic partners," explained Morgan Kline, CEO and Co-Founder of Burn Boot Camp.
  • "Here at the Muscular Dystrophy Association, we stand hand in hand with Burn Boot Camp in our shared commitment to empower communities nationwide.
  • MDA and Burn Boot Camp will be posting throughout the campaign on social media using @MDAorg and @burnbootcamp with #BeTheirMuscle.

Paragonix Technologies Announces Nationwide Commercial Availability of FDA-Cleared BAROguard™ Donor Lung Preservation System

Retrieved on: 
Thursday, April 4, 2024
FDA, Health Technology, Health, Medical Devices, Lung, Massachusetts General Hospital, International Society, Transplant, Patient, Duke University Hospital, Research, Standard of care, Lung transplantation, MD, Surgeon, MSC, UCSF Medical Center, Atmosphere, Hospital, UCLA, Heart, UCLA Health, Medical device

Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .

Key Points: 
  • Paragonix Technologies, Inc. , a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System .
  • First-of-its-kind, the novel BAROguard system combines clinically proven hypothermic preservation techniques alongside active airway management control to ensure that donor lungs maintain optimal conditions during transport for maximum protection.
  • Paragonix Technologies received FDA 510(k) clearance for the device in August 2023, and conducted its first-in-human case at Duke University Medical Center in November 2023.
  • “The commercial launch of BAROguard represents a significant breakthrough for the organ transplantation industry,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies.

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Citigroup, Rabin Medical Center, Biomedicine, Biomedical engineering, Partnership, Tiger Management, Business, Duke University, Duke University Hospital, NDA, Acquisition, Credit Suisse, University, MD Anderson Cancer Center, Therapy, Bangladesh Technical Education Board, STAT3, Pharmaceutical industry

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.

Key Points: 
  • Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.
  • Formerly, Mr. Shah was a healthcare investment banker for global investment banks Citigroup and Credit Suisse.
  • Newly appointed board member Dr. Wirk has more than 20 years of investment experience in public and private life science companies.
  • “The appointment of Sujal as Chairman and the addition of Shaheen to Tvardi’s Board of Directors are instrumental to the success of Tvardi,” said Imran Alibhai, Ph.D., CEO of Tvardi.

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients

Retrieved on: 
Friday, March 8, 2024
BVA, Anemia, Blood, Kidney, Duke University Hospital, Risk, Conference, Heart failure, Prevalence, Patient, Kidney disease, Diagnosis, Correlation, THT, Pressure, Medical imaging

Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.

Key Points: 
  • Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.
  • The study, titled, ‘Blood Volume Profiles and Correlations with Pressures in Heart Failure with Impaired Renal Function,’ aimed to answer if the degree of renal impairment in heart failure patients impacts volume status, the pressure-volume relationship, and the prevalence and types of anemia.
  • Veraprapas Kittipibul M.D., lead investigator of the study concluded that:
    Heterogeneity in volume exists across renal function which can only be accurately measured with BVA.
  • Patients with large volume expansion had worsening renal function, showing the urgent need for care.

FIRE1 Completes Enrollment in U.S. Early Feasibility Study of Innovative Remote Heart Failure Monitoring System

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Surgery, Health Technology, Clinical Trials, Cardiology, Division, Hypervolemia, Surgeon, Rochester General Hospital, Ohio State University, Weill Cornell Medicine, Hospital, Duke University Hospital, Inferior vena cava, Heart failure, Patient, Medicine, IVC, Ageing, Physician, Pressure, Medical imaging

Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.

Key Points: 
  • Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.
  • The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.
  • FIRE1 seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a consumer-friendly device at home, similar to how continuous glucose monitoring transformed diabetes care.
  • “It is gratifying to see the physician interest in our novel technology that earlier studies suggest should be a more sensitive measure than pressure in monitoring heart failure,” said FIRE1 CEO and President Conor Hanley.

Heart Failure Monitoring Technology Doubles Sensitivity for Predicting Events While Minimizing False Alerts Versus Standard of Care

Retrieved on: 
Wednesday, March 6, 2024
SAN, Algorithm, Peter Hancock (professor), MD, FDA, MHS, Hospital, Standard of care, Duke University Hospital, Heart failure, Biomarker, Patient, THT, Observational study, Research, Pharmaceutical industry

SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.

Key Points: 
  • SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.
  • It demonstrated this using the same monitoring routine patients already follow in weighing themselves daily and concurrently minimized false alerts for care teams, generating nearly 40 percent fewer overall alerts.
  • Over the course of the study, the Congestion Index correctly predicted 48 of 69 heart failure events (70%), demonstrating significantly higher sensitivity (p
  • In addition to demonstrating greater sensitivity in detecting heart failure events, the Congestion Index did so with a lower alert rate, generating only 2.58 alerts per patient-year compared to the 4.18 produced by the standard of care.

Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors

Retrieved on: 
Monday, February 12, 2024
Hospital, American Heart Association, Artificial intelligence, Society, University, American College, Health, American Surgical Association, Cardiothoracic surgery, Bangladesh Technical Education Board, Register, NIH, Duke University Hospital, JAMA, Physician, MDAI, International Society, General surgery, Abstract, Internal medicine, United, Society of Thoracic Surgeons, Research, Human services, Spectral, FDA, American College of Surgeons, National Science Foundation, American Burn Association, Lung transplantation, Publication, Medical device

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.

Key Points: 
  • DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.
  • Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
  • Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020.
  • "I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors.

National Academy of Medicine Member New President of The Obesity Society

Retrieved on: 
Thursday, February 1, 2024
Bias, The Obesity Society, Medical school, Growth, University, Metabolism, Science, Obesity, Duke University Hospital, Division, Society, National academy, Patient, Inborn errors of metabolism, Columbia University, Wellness, Executive Committee, ARD, Obesity medicine, Harvard Medical School, Education, Health equity, Doctor of Philosophy, Health, Cornier, Cedars-Sinai Medical Center, Clinical research, Internal medicine

ROCKVILLE, Md. , Feb. 1, 2024 /PRNewswire/ -- A member of the National Academy of Medicine is the new president of The Obesity Society (TOS), the organization announced today.

Key Points: 
  • , Feb. 1, 2024 /PRNewswire/ -- A member of the National Academy of Medicine is the new president of The Obesity Society (TOS), the organization announced today.
  • He also co-directs the Atrium Health Wake Forest Baptist Weight Management Center, where he oversees medical weight management programs.
  • "I am honored to serve as president of TOS during such a transformative time in the field of obesity.
  • The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects.

Stories about war, violence and hate crime can cause anxiety, anger and depression in kids -- here's how to discuss bad news with your children

Retrieved on: 
Thursday, January 4, 2024
Duke University Hospital, Attention, Risk, Caregiver, Friends, Cyclone, Depression, Student, Psychiatry, Hatred, Parent, Hamas, Grammatical mood, Violence, Anxiety, Privacy, Emotion, Love, Association, Sleep, Tantrum, Social media, Face, American Association, Television, Suicide, Hearing, Toy

We know from much academic work in this area that we see an increase in anxiety, in worries, in fears, in depression and, sometimes, an increase in anger.

Key Points: 
  • We know from much academic work in this area that we see an increase in anxiety, in worries, in fears, in depression and, sometimes, an increase in anger.
  • We see an increased sense of hopelessness, and then, at the extreme, an increase in risk for suicide.
  • How should parents prepare for a conversation with their children about hate and hate crimes, war and violence?
  • Robin Gurwitch: Before we even begin to talk to our children, as adults we have to put in place our thoughts and feelings.
  • What are the values and beliefs that we hold in the face of these types of events?
  • Talk to friends and other trusted relatives to make sure that you have a handle on your emotions.
  • What specific advice do you have for talking to very young children – and to older children?
  • Robin Gurwitch: With really young children, under preschool age and younger, they probably don’t know and won’t understand what’s going on.


Robin Gurwitch receives funding from SAMHSA. Some of my efforts are funded as part of the National Child Traumatic Stress Network, which is funded by SAMHSA. All work is non-profit. All funds for salary support go through my employer, not directly to me.

The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis

Retrieved on: 
Monday, December 18, 2023
School, Faculty, Duke University Hospital, Partnership, Prognosis, Research, Pathology, Inflammation, Disease, Johns Hopkins University, Doctor of Philosophy, Sarcoidosis, Transplant, Duke University, University, 3D, University of Pennsylvania, Assistant, Diagnosis, Public health, JHU, FSR, Medical device

CHICAGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Foundation for Sarcoidosis Research (FSR) announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.

Key Points: 
  • CHICAGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Foundation for Sarcoidosis Research (FSR) announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.
  • With this grant, we aim to improve the specificity of cardiac sarcoidosis diagnosis with FDG-PET using a novel strategy incorporating combined SGLT1/2 inhibition with sotagliflozin.
  • “The 2023 FSR Sarcoidosis Cardiac Grant award will allow us to use the novel 3D multi-omic pathology to determine unique properties of vasculature surrounding cardiac sarcoidosis granulomas and find new potential biomarker targets and histological criteria for cardiac sarcoidosis diagnosis.
  • FSR is dedicated to accelerating sarcoidosis research through fellowships, small grants, large grants, and disease specific grants to advance sarcoidosis research and advance care for those living with sarcoidosis.